Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
The Danish biotech company confirmed the global study will begin in the second half of 2026
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
The submission is backed by positive results from the Phase 3 AFFIRM study
The approval was driven by data from the Phase III TULIP-SC trial
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
Subscribe To Our Newsletter & Stay Updated
